Cost Effectiveness and Ease of Administration of Low Molecular Weight Heparin in Deep Vein Thrombosis

Thromb Haemost 1994; 72(02): 328-329
DOI: 10.1055/s-0038-1648865

Letter to the Editor

Schattauer GmbH Stuttgart

Authors

C P Teo

Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore
H L Lim

Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore
Y K Kueh

Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore

References
1 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin fragmin: results of a doubleblind randomized study. Circulation 1989; 80: 935-940
2 Simoneau G. for the TVPENOX Group Study. Subcutanous fixed dose of enoxaparine (E) versus intravenous adjusted dose of unfractionated heparin(UH) in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1991: 65-754
3 Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractioned heparin in the treatmentof deep vein thrombosis: a collaborative European multicentre study. Thromb Haemost 1991; 65: 1058-1063
4 Prandoni P, Lensing AWA, Buller HP, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Ten Cate JW. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximaldeep-vein thrombosis. Lancet 1992; 339: 441-445
5 Levesque H, Vasse D, Legallicier B, Callieux N, Moore N, Borg JY, Cour-tois H. Letter to Lancet 1993; 341: 824-825